Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 02, 2023

SELL
$103.46 - $126.29 $906,516 - $1.11 Million
-8,762 Reduced 23.69%
28,231 $3.03 Million
Q4 2022

Jan 30, 2023

SELL
$36.06 - $117.21 $208,787 - $678,645
-5,790 Reduced 13.53%
36,993 $4.07 Million
Q3 2022

Nov 08, 2022

BUY
$28.17 - $59.01 $158,371 - $331,754
5,622 Added 15.13%
42,783 $2.53 Million
Q2 2022

Aug 04, 2022

BUY
$22.39 - $38.94 $111,345 - $193,648
4,973 Added 15.45%
37,161 $1.05 Million
Q1 2022

May 05, 2022

BUY
$30.13 - $50.0 $436,553 - $724,450
14,489 Added 81.86%
32,188 $1.22 Million
Q4 2021

Feb 02, 2022

BUY
$22.28 - $39.54 $175,610 - $311,654
7,882 Added 80.29%
17,699 $700,000
Q3 2021

Nov 02, 2021

BUY
$20.89 - $26.96 $2,444 - $3,154
117 Added 1.21%
9,817 $233,000
Q2 2021

Aug 02, 2021

BUY
$16.8 - $29.65 $162,960 - $287,605
9,700 New
9,700 $238,000

Others Institutions Holding RXDX

About Prometheus Biosciences, Inc.


  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.